IJMSC editor-in-chief, François Bethoux, MD, and colleagues cover idea generation, poster conversion, literature reviews, and peer review in a 4-part webinar series for MS clinicians.
Commentary|Articles|February 3, 2026
Women Physicians Day 2026: Supporting Women With MS Through Reproductive and Life Stage Transitions
In honor of National Women Physicians Day, held February 3, 2026, a trio of women clinicians highlighted the importance of individualized care for women living with multiple sclerosis.
Advertisement
Advertisement
Women with multiple sclerosis often navigate reproductive health, pregnancy, and menopause alongside ongoing disease management. Hormonal changes, family planning decisions, and life stage transitions can influence symptoms, treatment timing, and overall wellbeing. A care approach that integrates neurologic and women’s health considerations helps ensure management strategies align with both disease control and personal health goals.1
Related to this article
Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.
Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.
Terrie Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.
New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Here's some of what is coming soon to NeurologyLive® this week.
Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.
Advertisement
Advertisement